Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alfresa HoldingsARHCF 82 EV-to-EBIT is 3.77 as of Aug. 11, 2026, which is 33% below its 10-year median of 5.60. GuruFocus rates ARHCF with a GF Score™ of 82/100 and a GF Value™ of $12.24 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 96 Medical Distribution companies, Alfresa Holdings ranks better than 93.75% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Alfresa Holdings's Enterprise Value for the quarter that ended in Mar. 2026 was $1,168 Mil.
Alfresa Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $385 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alfresa Holdings EV-to-EBIT Related Terms
Alfresa Holdings EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Alfresa Holdings's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Alfresa Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alfresa Holdings EV-to-EBIT vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Alfresa Holdings's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Alfresa Holdings's EV-to-EBIT falls into.
Alfresa Holdings's current Enterprise Value is $1,453 Mil.
Alfresa Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $385 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alfresa Holdings (ARHCF) has a EV-to-EBIT of 3.77 as of Aug. 11, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Alfresa Holdings and its competitors. This is 33% below median its historical median of 5.60. Over the past decade, Alfresa Holdings' EV-to-EBIT has ranged from 2.84 to 10.16. According to the industry distribution chart, Alfresa Holdings ranks #6 out of 96 companies in the Medical Distribution industry, placing it in the top 6.2%.
Is Alfresa Holdings' EV-to-EBIT too high?
Alfresa Holdings' current EV-to-EBIT of 3.77 is 33% below median its 10-year median of 5.60. Over the past 10 years, this metric has ranged from a low of 2.84 to a high of 10.16. The Medical Distribution industry median EV-to-EBIT is 11.94. Alfresa Holdings' value of 3.77 is 68.4% below this industry median. Based on the distribution chart, Alfresa Holdings ranks #6 out of 96 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Alfresa Holdings has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alfresa Holdings' EV-to-EBIT compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Alfresa Holdings ranks #6 out of 96 companies for EV-to-EBIT. This places Alfresa Holdings in the top 6% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 11.94. Alfresa Holdings' value of 3.77 is 68.4% below this benchmark. Historically, Alfresa Holdings' own EV-to-EBIT has ranged from 2.84 to 10.16 over the past decade. While the company's 10-year median is 5.60 vs. the industry median of 11.94, Alfresa Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Distribution company?
The median EV-to-EBIT among Medical Distribution companies is 11.94, based on 96 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alfresa Holdings's current EV-to-EBIT of 3.77 is 68.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Alfresa Holdings and its competitors. For the Medical Distribution industry, the median EV-to-EBIT is 11.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alfresa Holdings's current EV-to-EBIT is 3.77, which is 33% below median its own 10-year median of 5.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alfresa Holdings stock overvalued right now?
Based on GuruFocus' analysis, Alfresa Holdings (ARHCF) is currently considered Modestly Overvalued. The stock's GF Value™ is $12.24, compared to a current price of $14.00 — trading 14.4% above its estimated fair value. The current EV-to-EBIT is 3.77, which is 33% below median its 10-year median of 5.60 and 68.4% below the Medical Distribution industry median of 11.94. Alfresa Holdings' overall GF Score™ is 82/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Alfresa Holdings (ARHCF), the current EV-to-EBIT is 3.77 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alfresa Holdings (ARHCF) Overvalued in 2026?
Based on GuruFocus' analysis, Alfresa Holdings stock appears to be overvalued.
The current stock price of $14.00 is trading 14.4% above its estimated GF Value™ of $12.24.
GuruFocus considers Alfresa Holdings to be Modestly Overvalued.
Key valuation signals for ARHCF:
EV-to-EBIT: 3.77 (33% below median its 10-year median of 5.60)
GF Value™: $12.24 vs. price of $14.00 (14.4% above fair value)
Industry Position: 68.4% below the Medical Distribution median (#6 of 96)
No single metric tells the full story. See the ARHCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alfresa Holdings Corp is engaged in the pharmaceutical distribution and related businesses. The company operates through four reportable segments: Wholesale business of medical drugs, Self-Medication Wholesale Business, Pharmaceutical Manufacturing Business, and Medical-Related Business. Its operations include the wholesale of ethical and over-the-counter pharmaceuticals, the manufacture and sale of pharmaceuticals, medical testing reagents, and medical equipment, as well as the operation of dispensing pharmacies.
82GF Score
Get the complete analysis for ARHCF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARHCF has been successfully added to your 
